Analyst: Amgen Can Afford Actelion but Deal Unlikely

Amgen Inc could pay more than $10 billion for Swiss biotech firm Actelion Ltd without hurting its 2011 earnings, but the deal is unlikely to happen given the lack of business overlap that would allow for cost savings, according to an analyst.
ABC News